PROCEPT BioRobotics (NASDAQ:PRCT) stock is trading on Monday after the company released better-than-expected third-quarter earnings. The company reported EPS loss of $(0.40), down from $(0.51) a year ...

PROCEPT BioRobotics Corporation (NASDAQ:PRCT) ranks among the top robotics to buy according to analysts. On August 7, Wells Fargo maintained its Overweight rating on PROCEPT BioRobotics Corporation ...

BofA Securities recently downgraded PROCEPT BioRobotics from Buy to Neutral, citing slowing utilization growth and moderating system sales for its Aquablation technology amid tighter hospital capital ...

Procept BioRobotics' surgical bots tackle a perplexing prostate problem, boosting the San Jose company's financial results. Newly approved cancer drug lands $8 ...

Why is this unit important? The next frontier in robotics will take inspiration from biology to design robots that are soft, smart, green and social to address important societal challenges. From ...

Case Western Reserve roboticist Roger Quinn, neuroscientist Hillel Chiel to lead $8 million, five-year National Science Foundation NeuroNex Network project seeking next level of control of ...

The latest price target for PROCEPT BioRobotics (NASDAQ:PRCT) was reported by Truist Securities on December 18, 2025. The analyst firm set a price target for $47.00 expecting PRCT to rise to within 12 ...

SAN JOSE, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing ...

Total revenue of $79.2 million for the second quarter of 2025, an increase of 48% compared to the prior year period in 2024 U.S. handpiece and consumables revenue of $43.1 million for the second ...

Procept BioRobotics reported its second-quarter 2025 earnings, exceeding expectations with an actual EPS of -$0.35, compared to a forecast of -$0.41. Revenue also surpassed projections, reaching $79.2 ...